Oct 28 2009
Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that global contract research organization (CRO) Omnicare Clinical Research has attained Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win® program for CROs and other service providers. With this accreditation, Omnicare Clinical Research can now offer sponsors a comprehensive suite of Medidata Rave® services that will enable them to cost-effectively increase clinical research efficiencies across all therapeutic areas and trial phases.
As a leading Phase I through IV CRO with locations in 31 countries, Omnicare Clinical Research manages trials for pharmaceutical, biotechnological, nutraceutical and medical device companies of all sizes and specialties. The CRO first joined Medidata’s ASPire to Win program in January 2009 in order to field increasing demand for the Medidata Rave electronic clinical data capture (EDC), reporting and management solution.
Omnicare Clinical Research’s clinical data management force of more than 60 programming professionals supports more than 100 EDC database configurations each year. As a Rave Accredited Plus partner, Omnicare Clinical Research is now able to independently offer its customers end-user training, study build, reporting, outputs, integration and migration services for the Medidata Rave platform.
“From large, global pharmaceutical companies to specialty biotechs, our customers continue to view Medidata Rave as a critical component of the clinical development process and rely on the solution as a hub of clinical data,” said Michael Burton, Director of eClinical Solutions at Omnicare Clinical Research. “The ASPire to Win program has been instrumental in allowing us to easily and efficiently meet our customers’ needs for EDC at all phases of clinical trials.”
“Omnicare Clinical Research has consistently shared our eClinical vision of driving efficiencies and quality across the clinical development process through best-of-breed clinical trial technology,” said Graham Bunn, Vice President of Global Partnership at Medidata Solutions. “Omnicare’s ASPire to Win accreditation will further enable them to deliver the Medidata Rave tools and services that sponsors need to execute successful trials of all sizes, phases and therapeutic areas.”
Medidata first announced ASPire to Win in April 2005 as a partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include more than 20 partners, ranging from smaller clinical consultancies to large, global CROs. For more information about the ASPire to Win program, visit www.mdsol.com/partnerships/cros.htm.
SOURCE Omnicare Clinical Research
BMI's influence on disease pathogenesis uncovered in new research